Study:
Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma
Rationale:
Interferon alfa may interfere with the growth of cancer cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Interleukin-2 may stimulate a person`s white blood cells to kill melanoma cells. It is
not yet known whether interferon alfa is more effective with or without combination
chemotherapy and interleukin-2 for melanoma.
Purpose:
Randomized phase III trial to compare the effectiveness of interferon alfa with or
without combination chemotherapy consisting of cisplatin, vinblastine, and dacarbazine, plus
interleukin-2, in treating patients who have melanoma.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Melanoma (Skin) |
Biological: interleukin-2
Biological: filgrastim
Biological: interferon alfa
Drug: cisplatin
Drug: dacarbazine
Drug: vinblastine |
Phase 3 |
Verified by
Southwest Oncology Group
November, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00006237
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Lawrence E. Flaherty, MD., Study Chair
John A. Thompson, MD., Principal Investigator
John T. Vetto, MD, FACS., Principal Investigator
Michael B. Atkins, MD., Study Chair
John M. Kirkwood, MD., Principal Investigator
Frank Haluska, MD, PhD., Study Chair
Alberto S. Pappo, MD., Principal Investigator